Centre of Evidence Based Dermatology
  • Print

CEBD Coronavirus Dermatology Resource

 

Journal articles - Coronavirus and psoriasis

Please see also Guidelines page and Implications of coronavirus for use of biologics and other immune modulating therapies

Vaccination against SARS-COV-2 and psoriasis: The three things every dermatologist should know.
Diotallevi F, Campanati A, Radi G, Martina E, Rizzetto G, Barbadoro P, D'Errico MM, Offidani A.
J Eur Acad Dermatol Venereol. 2021 Mar 29. doi: 10.1111/jdv.17256. Online ahead of print. Review / commentary.
https://doi.org/10.1111/jdv.17256

Position statement of the EADV Melanoma Task Force on recommendations for the management of cutaneous melanoma patients during COVID-19.
Arenbergerova M, Lallas A, Nagore E, Rudnicka L, Forsea A, Pasek M, Meier F, Peris K, Olah J, Posch C.
J Eur Acad Dermatol Venereol. 2021 Mar 29. doi: 10.1111/jdv.17252. Online ahead of print. Guideline.
https://doi.org/10.1111/jdv.17252

Psoriasis management during the COVID-19 pandemic: Recommendations by SIG Psoriasis (IADVL Academy).
Ganguly S, Parthasaradhi A, Thomas J, Arora S, Kumar P, Pradhan S, Saraswat A, Singh V, Komeravalli H.
Indian Dermatol Online J. 2021 Jan 16;12(1):58-65. doi: 10.4103/idoj.IDOJ_685_20. eCollection 2021 Jan-Feb. Review & recommendations.
https://doi.org/10.4103/idoj.idoj_685_20

Risk of COVID-19 infection, hospitalization, and mortality in patients with psoriasis treated by interleukin-17 inhibitors.
Kridin K, Schonmann Y, Solomon A, Damiani G, Tzur Bitan D, Onn E, Weinstein O, Cohen AD.
J Dermatolog Treat. 2021 Mar 24:1-28. doi: 10.1080/09546634.2021.1905766. Online ahead of print. Cohort study.
https://doi.org/10.1080/09546634.2021.1905766

Risk of COVID-19 infection in adult patients with atopic eczema and psoriasis: a single centre, cross-sectional study.
Yiu ZZN, Harding G, Griffiths CEM, Warren RB, McMullen E, Hunter HJA. Cross-sectional study.
Br J Dermatol. 2021 Mar 17. doi: 10.1111/bjd.20062. Online ahead of print.
https://doi.org/10.1111/bjd.20062

Psoriasis and psoriatic arthritis in the context of the COVID-19 pandemic: A plenary session from the GRAPPA 2020 Annual Meeting.
Mease PJ, Calabrese LH, Callis Duffin K, Haberman RH, Firmino R, Scher JU, Schick L, Winthrop K, Merola JF.
J Rheumatol. 2021 Mar 15:jrheum.201671. doi: 10.3899/jrheum.201671. Online ahead of print. Report / commentary.
https://doi.org/10.3899/jrheum.201671

Response to "New-onset pustular psoriasis in the setting of severe acute respiratory syndrome coronavirus 2 infection causing coronavirus disease 2019".
Assan F, Sbidian E, Bachelez H.
JAAD Case Rep. 2021 Mar 4. doi: 10.1016/j.jdcr.2021.02.024. Online ahead of print. Commentary.
https://doi.org/10.1016/j.jdcr.2021.02.024

COVID-19 vaccination and psoriatic patients under biologics: real-life evidence on safety and effectiveness from Italian vaccinated healthcare workers.
Damiani G, Allocco F; Young Dermatologists Italian Network, Malagoli PO.
Clin Exp Dermatol. 2021 Mar 5. doi: 10.1111/ced.14631. Online ahead of print. Case reports.
https://doi.org/10.1111/ced.14631

Certolizumab pegol in the treatment of psoriasis: Real-life data.
Turkmen M, Dogan S.
Dermatol Ther. 2021 Mar 4:e14929. doi: 10.1111/dth.14929. Online ahead of print. Retrospective cohort study.
https://doi.org/10.1111/dth.14929

Insights into COVID-19 vaccination in patients with chronic plaque psoriasis on systemic treatments.
Gisondi P, Geat D, Naldi L, Piaserico S.
J Eur Acad Dermatol Venereol. 2021 Mar 1. doi: 10.1111/jdv.17200. Online ahead of print. Commentary.
https://doi.org/10.1111/jdv.17200

SARS-CoV-2 vaccination and immunotherapy in dermatology.
Rodríguez-Villa Lario A, Vega-Díez D, Polo-Rodríguez I.
Actas Dermosifiliogr. 2021 Feb 27:S0001-7310(21)00104-6. doi: 10.1016/j.ad.2021.02.006. Online ahead of print. Spanish, English version to follow. Commentary / review.
https://doi.org/10.1016/j.ad.2021.02.006

Furin expression in patients with psoriasis-A patient cohort endangered to SARS-COV2?
Graier T, Golob-Schwarzl N, Weger W, Benezeder T, Painsi C, Salmhofer W, Wolf P.
Front Med (Lausanne). 2021 Feb 10;8:624462. doi: 10.3389/fmed.2021.624462. eCollection 2021. Observational study.
https://doi.org/10.3389/fmed.2021.624462

Impact of the COVID-19 pandemic on children with psoriasis.
Beytout Q, Pepiot J, Maruani A, Devulder D, Aubert R, Beylot-Barry M, Amici JM, Jullien D, Mahé E; Association France Psoriasis; Research Group on Psoriasis of the French Society of Dermatology (GrPso); Research Group of the French Society of Pediatric Dermatology (SFPD).
Ann Dermatol Venereol. 2021 Feb 23:S0151-9638(21)00027-2. doi: 10.1016/j.annder.2021.01.005. Online ahead of print. Survey.
https://doi.org/10.1016/j.annder.2021.01.005

Intention of COVID-19 vaccination among psoriatic patients compared to immunosuppressed patients with other skin diseases and factors influencing their decision.
Sotiriou E, Bakirtzi K, Papadimitriou I, Paschou E, Vakirlis E, Lallas A, Ioannides D.
Br J Dermatol. 2021 Feb 20. doi: 10.1111/bjd.19882. Online ahead of print. Cross-sectional study.
https://doi.org/10.1111/bjd.19882

Is SARS-CoV-2 screening test indicated for psoriasis patients candidate to biologic therapy?
Piaserico S, Gisondi P, Cazzaniga S, Girolomoni G, Calzavara-Pinton PG, Naldi L.
J Eur Acad Dermatol Venereol. 2021 Feb 15. doi: 10.1111/jdv.17175. Online ahead of print. Review / commentary.
https://doi.org/10.1111/jdv.17175

A survey of psoriasis patients on biologics during COVID-19: a high-epidemic area experience - Franche Comté, France.
Gallais-Serezal I, Puzenat E, Moreau J, Dresco F, Pelletier F, Nardin C, Aubin F.
Eur J Dermatol. 2021 Feb 12. doi: 10.1684/ejd.2020.3960. Online ahead of print. Survey / cross-sectional study.
https://doi.org/10.1684/ejd.2020.3960

Concerns and perceptions of patients with psoriatic disease during the COVID-19 pandemic: results from a two-wave survey by the National Psoriasis Foundation.
Gondo GC, Bell SJ, Slayden J, Ullmann G, Blauvelt A.
J Eur Acad Dermatol Venereol. 2021 Feb 15. doi: 10.1111/jdv.17173. Online ahead of print. Survey / cross-sectional study.
https://doi.org/10.1111/jdv.17173

COVID-19 and biologic therapies in dermatology: seroprevalence survey and severity analysis in a tertiary hospital in Spain.
Barrutia L, Volo V, Ruíz-Sánchez D, Valtueña J, Aguado García A, Manchado López P.
Int J Dermatol. 2021 Feb 9. doi: 10.1111/ijd.15467. Online ahead of print. Cross-sectional study.
https://doi.org/10.1111/ijd.15467

Topical steroids and topical tacrolimus appear safe regarding in relation to the COVID-19 epidemic.
Souaid K, Klejtman T, Kramkimel N, Isnard C, Dupin N, Aractingi S.
Ann Dermatol Venereol. 2021 Jan 8:S0151-9638(21)00003-X. doi: 10.1016/j.annder.2020.12.001. Online ahead of print. Cohort study.
https://doi.org/10.1016/j.annder.2020.12.001

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations.
Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Csörgö Z, Boonen H, De Jong E, Garcia-Doval I, Gisondi P, Kaur-Knudsen D, Mahil S, Mälkönen T, Maul JT, Mburu S, Mrowietz U, Reich K, Remenyik E, Rønholt KM, Sator PG, Schmitt-Egenolf M, Sikora M, Strömer K, Sundnes O, Trigos D, Van Der Kraaij G, Yawalkar N, Dressler C.
J Eur Acad Dermatol Venereol. 2021 Feb;35(2):281-317. doi: 10.1111/jdv.16926. Guideline.
https://doi.org/10.1111/jdv.16926

A psoriatic patient-based survey on the understanding of the use of vaccines while on biologics during the COVID-19 pandemic.
Le H, Vender RB.
J Cutan Med Surg. 2021 Jan 27:1203475421991126. doi: 10.1177/1203475421991126. Online ahead of print. Survey.
https://doi.org/10.1177/1203475421991126

Adherence to biological therapy in dermatological patients during the COVID-19 pandemic in Western Sicily.
Tilotta G, Pistone G, Caruso P, Gurreri R, Castelli E, Curiale S, Caputo V, Bongiorno MR.
Int J Dermatol. 2021 Feb;60(2):248-249. doi: 10.1111/ijd.15352. Epub 2020 Dec 8. Cross-sectional study / audit.
https://doi.org/10.1111/ijd.15352

A meta-analysis of comorbidities in COVID-19: Which diseases increase the susceptibility of SARS-CoV-2 infection?
Singh MK, Mobeen A, Chandra A, Joshi S, Ramachandran S.
Comput Biol Med. 2021 Jan 16;130:104219. doi: 10.1016/j.compbiomed.2021.104219. Online ahead of print. Genetic meta-analysis.
https://doi.org/10.1016/j.compbiomed.2021.104219

Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies.
Patrick MT, Zhang H, Wasikowski R, Prens EP, Weidinger S, Gudjonsson JE, Elder JT, He K, Tsoi LC.
J Allergy Clin Immunol. 2021 Jan 21:S0091-6749(21)00084-1. doi: 10.1016/j.jaci.2021.01.006. Online ahead of print. Genetic meta-analysis.
https://doi.org/10.1016/j.jaci.2021.01.006

Exacerbation of psoriasis following hydroxychloroquine in a patient with suspected COVID-19.
Öncü INS, Güler D, Gürel G.
Dermatol Ther. 2021 Jan 24:e14806. doi: 10.1111/dth.14806. Online ahead of print. Case report.
https://doi.org/10.1111/dth.14806

Safety of biologics for psoriasis patients during the COVID-19 pandemic: the experience from Wuhan, China.
Zhao L, Du H, Alamgir M, Yang J, Miao X, Jiang B, Xia Y, Lou Y, Wang Y, Shen C, Zhu J, Chung WH, Li Y, Tao J.
Eur J Dermatol. 2020 Dec 1;30(6):738-740. doi: 10.1684/ejd.2020.3908. Cohort study.
https://doi.org/10.1684/ejd.2020.3908

National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 2 - Advances in Psoriatic Disease Management, COVID-19 Vaccines, and COVID-19 Treatments.
Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, Dommasch ED, Feldman SR, Gladman D, Kircik L, Lebwohl M, Lo Re V 3rd, Martin G, Merola JF, Scher JU, Schwartzman S, Treat JR, Van Voorhees AS, Ellebrecht CT, Fenner J, Ocon A, Syed MN, Weinstein EJ, Gondo G, Heydon S, Koons S, Ritchlin CT.
J Am Acad Dermatol. 2021 Jan 7:S0190-9622(21)00016-5. doi: 10.1016/j.jaad.2020.12.058. Online ahead of print. Guideline.
https://doi.org/10.1016/j.jaad.2020.12.058

Risk mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey.
Mahil SK, Yates M, Langan SM, Yiu ZZN, Tsakok T, Dand N, Mason KJ, McAteer H, Meynell F, Coker B, Vincent A, Urmston D, Vesty A, Kelly J, Lancelot C, Moorhead L, Bachelez H, Bruce IN, Capon F, Contreras CR, Cope AP, De La Cruz C, Di Meglio P, Gisondi P, Hyrich K, Jullien D, Lambert J, Marzo-Ortega H, McKinnes I, Naldi L, Norton S, Puig L, Sengupta R, Spuls P, Torres T, Warren RB, Waweru H, Weinman J, Griffiths CM, Barker JN, Brown MA, Galloway JB, Smith CH.
Br J Dermatol. 2020 Dec 23. doi: 10.1111/bjd.19755. Online ahead of print. Survey / cross-sectional study.
https://doi.org/10.1111/bjd.19755

Surveillance of psoriatic patients on biologic treatment during the COVID-19 pandemic: A single-center experience.
Polat Ekinci A, Pehlivan G, Gökalp MO.
Dermatol Ther. 2020 Dec 23. doi: 10.1111/dth.14700. Online ahead of print. Survey / cross-sectional study.
https://doi.org/10.1111/dth.14700

Safety of secukinumab treatment in COVID-19 affected psoriatic patients.
Mugheddu C, Sanna S, Atzori L, Rongioletti F.
Dermatol Ther. 2020 Dec 27:e14710. doi: 10.1111/dth.14710. Online ahead of print. Case reports.
https://doi.org/10.1111/dth.14710

Obesity - A risk factor for psoriasis and COVID-19.
Llamas-Velasco M, Ovejero-Merino E, Salgado-Boquete L.
Actas Dermosifiliogr. 2020 Dec 24:S0001-7310(20)30548-2. doi: 10.1016/j.ad.2020.12.001. Online ahead of print. Review.
https://doi.org/10.1016/j.ad.2020.12.001

The impact of COVID-19 in patients with psoriasis: A multicentre study in Istanbul.
Polat AK, Topal IO, Karadag AS, Aksoy H, Aksu AEK, Ozkur E, Akbulut TO, Demir FT, Engin B, Uzuncakmak TK, Altunay IK.
Dermatol Ther. 2020 Dec 22. doi: 10.1111/dth.14691. Online ahead of print. Survey / cross-sectional study.
https://doi.org/10.1111/dth.14691

Understanding views of patients on biologics for psoriasis amid the COVID-19 pandemic.
Pandher K, Porter CL, Patel HS, Huang WW, Feldman SR.
J Eur Acad Dermatol Venereol. 2020 Dec 17. doi: 10.1111/jdv.17091. Online ahead of print. Survey / cross-sectional study.
https://doi.org/10.1111/jdv.17091

Psoriasis flare after influenza vaccination in Covid-19 era: a report of four cases from a single centre.
Munguía-Calzada P, Drake-Monfort M, Armesto S, Reguero-Del Cura L, López-Sundh AE, González-López MA.
Dermatol Ther. 2020 Dec 17:e14684. doi: 10.1111/dth.14684. Online ahead of print. Case reports & commentary.
https://doi.org/10.1111/dth.14684

The prevalence of SARS-CoV-2 infection and the severity of the course of COVID-19 in patients with psoriasis treated with biologic therapy.
Ciechanowicz P, Dopytalska K, Mikucka-Wituszyńska A, Dźwigała M, Wiszniewski K, Herniczek W, Szymańska E, Walecka I.
J Dermatolog Treat. 2020 Dec 14:1-12. doi: 10.1080/09546634.2020.1861177. Online ahead of print. Cross-sectional study.
https://doi.org/10.1080/09546634.2020.1861177

Response to Tembhre et al.: 'Enhanced expression of ACE2 in psoriatic skin and its upregulation in keratinocytes by interferon-gamma: Implication of inflammatory milieu in skin tropism of SARS-CoV-2'.
Gehlhausen JR, Ko CJ, Damsky W.
Br J Dermatol. 2020 Dec 10. doi: 10.1111/bjd.19714. Online ahead of print. Commentary.
https://doi.org/10.1111/bjd.19714

Biologic therapies, psoriasis, and COVID-19: Our experience at the psoriasis unit of the University of Naples Federico II.
Camela E, Fabbrocini G, Cinelli E, Lauro W, Megna M.
Dermatology. 2020 Dec 9:1-2. doi: 10.1159/000513575. Online ahead of print. Audit / cross-sectional study.
https://doi.org/10.1159/000513575

The risk of COVID-19 pandemic in patients with moderate to severe plaque psoriasis receiving systemic treatments.
Gisondi P, Bellinato F, Chiricozzi A, Girolomoni G.
Vaccines (Basel). 2020 Dec 2;8(4):E728. doi: 10.3390/vaccines8040728. Review.
https://doi.org/10.3390/vaccines8040728

The risk for severe COVID 19 in patients with autoimmune and/or inflammatory diseases: First wave lessons.
Druyan A, Lidar M, Brodavka M, Levy I, Barzilai A, Pavlotsky F.
Dermatol Ther. 2020 Dec 5. doi: 10.1111/dth.14627. Online ahead of print. Cross-sectional study / retrospective chart review.
https://doi.org/10.1111/dth.14627

Retention and survival rate of etanercept in psoriasis over 15 years and patient outcomes during the COVID-19 pandemic: The real-world experience of a single centre.
Onsun N, Güneş B, Yabacı A.
Dermatol Ther. 2020 Dec 3:e14623. doi: 10.1111/dth.14623. Online ahead of print. Cohort / registry study.
https://doi.org/10.1111/dth.14623

Characteristics, outcomes, and mortality amongst 133,589 patients with prevalent autoimmune diseases diagnosed with, and 48,418 hospitalised for COVID-19: a multinational distributed network cohort analysis.
Tan EH, Sena AG, Prats-Uribe A, You SC, Ahmed WU, Kostka K, Reich C, Duvall SL, Lynch KE, Matheny ME, Duarte-Salles T, Bertolin SF, Hripcsak G, Natarajan K, Falconer T, Spotnitz M, Ostropolets A, Blacketer C, Alshammari TM, Alghoul H, Alser O, Lane JCE, Dawoud DM, Shah K, Yang Y, Zhang L, Areia C, Golozar A, Relcade M, Casajust P, Jonnagaddala J, Subbian V, Vizcaya D, Lai LY, Nyberg F, Morales DR, Posada JD, Shah NH, Gong M, Vivekanantham A, Abend A, Minty EP, Suchard M, Rijnbeek P, Ryan PB, Prieto-Alhambra D.
medRxiv. 2020 Nov 27:2020.11.24.20236802. doi: 10.1101/2020.11.24.20236802. Multinational cohort study.
https://doi.org/10.1101/2020.11.24.20236802

Generalized pustular psoriasis following COVID-19.
Shahidi Dadras M, Diab R, Ahadi M, Abdollahimajd F.
Dermatol Ther. 2020 Nov 27:e14595. doi: 10.1111/dth.14595. Online ahead of print. Case report.
https://doi.org/10.1111/dth.14595

Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic: Risk analysis from the PSO-BIO-COVID observational study.
Talamonti M, Galluzzo M, Chiricozzi A, Quaglino P, Fabbrocini G, Gisondi P, Marzano AV, Potenza C, Conti A, Parodi A, Piaserico S, Bardazzi F, Argenziano G, Rongioletti F, Stingeni L, Micali G, Loconsole F, Rossi MT, Bongiorno MR, Feliciani C, Rubegni P, Amerio P, Fargnoli MC, Pigatto P, Savoia P, Nisticò SP, Giustini S, Carugno A, Cannavo' SP, Rech G, Prignano F, Offidani A, Lombardo M, Zalaudek I, Bianchi L, Peris K PSO-BIO-COVID study group.
Expert Opin Biol Ther. 2020 Nov 20. doi: 10.1080/14712598.2021.1853698. Online ahead of print. Cohort / registry study.
https://doi.org/10.1080/14712598.2021.1853698

Asymptomatic SARS-CoV2 infection in a patient receiving risankizumab, an inhibitor of IL-23.
Ward M, Gooderham M.
JAAD Case Rep. 2020 Nov 6. doi: 10.1016/j.jdcr.2020.10.032. Online ahead of print. Case report.
https://doi.org/10.1016/j.jdcr.2020.10.032

Does therapy with biological drugs influence COVID-19 infection? Observational, monocentric prevalence study on the clinical and epidemiological data of psoriatic patients treated with biological drugs or with topical drugs alone.
Brazzelli V, Isoletta E, Barak O, Barruscotti S, Vassallo C, Giorgini C, Michelerio A, Tomasini CF, Musella V, Klersy C.
Dermatol Ther. 2020 Nov 10:e14516. doi: 10.1111/dth.14516. Online ahead of print. Cohort study.
https://doi.org/10.1111/dth.14516

Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: a Northern Italy experience.
Paolo G, Stefano P, Luigi N, Paolo D, Andrea C, Piergiorgio M, Valerio MA, Federico B, Massimo G, Simone C, Antonio C; Collaborators in the studies of COVID-19 pandemic.
J Allergy Clin Immunol. 2020 Nov 5:S0091-6749(20)31558-X. doi: 10.1016/j.jaci.2020.10.032. Online ahead of print. Multi-centre cohort study.
https://doi.org/10.1016/j.jaci.2020.10.032

If skin is a potential host of SARS-CoV-2, IL-17 antibody could reduce the risk of COVID-19.
Xu Q, Chen L, Li X, Zheng J.
J Am Acad Dermatol. 2020 Nov 4:S0190-9622(20)32905-4. doi: 10.1016/j.jaad.2020.10.084. Online ahead of print. Case series & pathology study.
https://doi.org/10.1016/j.jaad.2020.10.084

Enhanced expression of ACE2 in psoriatic skin and its upregulation in keratinocytes by interferon-gamma: Implication of inflammatory milieu in skin tropism of SARS-CoV-2.
Tembhre MK, Parihar AS, Sharma VK, Imran S, Bhari N, Lakshmy R, Bhalla A.
Br J Dermatol. 2020 Nov 6. doi: 10.1111/bjd.19670. Online ahead of print. Case-control & pathology study.
https://doi.org/10.1111/bjd.19670

Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis suppurativa, and acne/rosacea during the COVID-19 pandemic.
Yim RM, Singh I, Armstrong AW.
Dermatol Online J. 2020 Oct 15;26(10):13030/qt0j5150df. Summary of international guidelines.
https://escholarship.org/uc/item/0j5150df

Immunosuppressive drugs for patients with psoriasis during the COVID-19 pandemic era. A review.
Sadeghinia A, Daneshpazhooh M.
Dermatol Ther. 2020 Nov 3. doi: 10.1111/dth.14498. Online ahead of print. Review.
https://doi.org/10.1111/dth.14498

COVID-19 in patients with cutaneous immune-mediated diseases in The Netherlands: real-world observational data.
de Wijs LEM, Joustra MM, Olydam JI, Nijsten T, Hijnen DJ.
J Eur Acad Dermatol Venereol. 2020 Nov 1. doi: 10.1111/jdv.17025. Online ahead of print. Survey / cross-sectional study.
https://doi.org/10.1111/jdv.17025

Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: a Biobadaderm cohort analysis.
Baniandrés-Rodríguez O, Vilar-Alejo J, Rivera R, Carrascosa JM, Daudén E, Herrera-Acosta E, Sahuquillo-Torralba A, Gómez-García FJ, Nieto-Benito LM, de la Cueva P, López-Estebaranz JL, Belinchón I, Ferrán M, Alsina M, Rodriguez L, Carretero G, García-Donoso C, Ballescá F, Llamas-Velasco M, Herrera-Ceballos E, Botella-Estrada R, Ruiz-Genao DP, Riera-Monroig J, Descalzo MA, García-Doval I; BIOBADADERM Study Group.
J Am Acad Dermatol. 2020 Oct 26:S0190-9622(20)32858-9. doi: 10.1016/j.jaad.2020.10.046. Online ahead of print. Multicentre, prospective cohort study.
https://doi.org/10.1016/j.jaad.2020.10.046

COVID-19 and psoriasis: Recommendation for patients on regular infliximab therapy.
Li S, Zhang S, Wu R, Su Y.
Dermatol Ther. 2020 Oct 30. doi: 10.1111/dth.14472. Online ahead of print. Cohort study.
https://doi.org/10.1111/dth.14472

Treating multidrug-resistant psoriasis with brodalumab, apremilast, methotrexate and prednisone combination therapy in the COVID-19 pandemic.
Armesto S, González Vela C, Sánchez J, Illaro A, Mayorga J, López Sundh AE, Naharro Fernández C, Palmou N, Gómez-Fernández C, González López MA, González-Gay MA.
Dermatol Ther. 2020 Oct 28. doi: 10.1111/dth.14464. Online ahead of print. Case report & commentary.
https://doi.org/10.1111/dth.14464

Pustular psoriasis exacerbated by COVID-19 in a patient with the history of psoriasis.
Shakoei S, Ghanadan A, Hamzelou S.
Dermatol Ther. 2020 Oct 28. doi: 10.1111/dth.14462. Online ahead of print. Case report.
https://doi.org/10.1111/dth.14462

New-onset pustular psoriasis in the setting of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causing Coronavirus Disease 2019 (COVID-19).
Mathieu RJ, Cobb CBC, Telang GH, Firoz EF.
JAAD Case Rep. 2020 Oct 16. doi: 10.1016/j.jdcr.2020.10.013. Online ahead of print. Case report.
https://doi.org/10.1016/j.jdcr.2020.10.013

Factors associated with adverse COVID-19 outcomes in patients with psoriasis - insights from a global registry-based study.
Mahil SK, Dand N, Mason KJ, Yiu ZZ, Tsakok T, Meynell F, Coker B, McAteer H, Moorhead L, Mackenzie T, Rossi MT, Rivera R, Mahe E, Carugno A, Magnano M, Rech G, Balogh EA, Feldman SR, De La Cruz C, Choon SE, Naldi L, Lambert J, Spuls P, Jullien D, Bachelez H, McMahon DE, Freeman EE, Gisondi P, Puig L, Warren RB, Di Meglio P, Langan SM, Capon F, Griffiths CE, Barker JN, Smith CH; PsoProtect study group.
J Allergy Clin Immunol. 2020 Oct 16:S0091-6749(20)31413-5. doi: 10.1016/j.jaci.2020.10.007. Online ahead of print. Patient registry study.
https://doi.org/10.1016/j.jaci.2020.10.007

A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic.
Hansel K, Zangrilli A, Bianchi L, Peris K, Chiricozzi A, Offidani A, Diotallevi F, Fargnoli MC, Esposito M, Amerio P, Gualdi G, Bianchi L, Stingeni L.
J Eur Acad Dermatol Venereol. 2020 Oct 20. doi: 10.1111/jdv.17003. Online ahead of print. Clinical trial.
https://doi.org/10.1111/jdv.17003

Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis.
Akiyama S, Hamdeh S, Micic D, Sakuraba A.
Ann Rheum Dis. 2020 Oct 13:annrheumdis-2020-218946. doi: 10.1136/annrheumdis-2020-218946. Online ahead of print. Systematic review.
https://doi.org/10.1136/annrheumdis-2020-218946

COVID, biologics, and psoriasis therapy.
Elston DM.
J Am Acad Dermatol. 2020 Sep 10:S0190-9622(20)32589-5. doi: 10.1016/j.jaad.2020.09.005. Online ahead of print. Editorial.
https://doi.org/10.1016/j.jaad.2020.09.005

The spectrum of dermatoses during the lockdown period of COVID-19 pandemic: Are papulosquamous disorders on the rise?
Singh AK, Rathod D, Gowda V, Bhargava S.
Skinmed. 2020 Aug 1;18(4):255-256. eCollection 2020. Commentary.
https://pubmed.ncbi.nlm.nih.gov/33050994/

Evaluation of the effect of COVID-19 pandemic on dermatological diseases with Dermatological Quality Life Index.
Daye M, Temiz SA, Işık B, Dursun R, Ataseven A.
Dermatol Ther. 2020 Oct 6:e14368. doi: 10.1111/dth.14368. Online ahead of print. Prospective cohort study.
https://doi.org/10.1111/dth.14368

Secukinumab lowers expression of ACE2 in affected skin of patients with psoriasis.
Krueger JG, Murrell DF, Garcet S, Navrazhina K, Lee PC, Muscianisi E, Blauvelt A.
J Allergy Clin Immunol. 2020 Sep 28:S0091-6749(20)31332-4. doi: 10.1016/j.jaci.2020.09.021. Online ahead of print. Research study.
https://doi.org/10.1016/j.jaci.2020.09.021

Endocrinological disorders and inflammatory skin diseases during COVID-19 outbreak. A review of the literature.
Marasca C, Fabbrocini G, Barrea L, Capasso G, Di Guida A, Cinelli E, Fontanella G.
Minerva Endocrinol. 2020 Sep 24. doi: 10.23736/S0391-1977.20.03248-4. Online ahead of print. Review.
https://doi.org/10.23736/s0391-1977.20.03248-4

Mask induced psoriasis lesions as Köebner phenomenon during COVID 19 pandemic.
Mutalik SD, Inamadar AC.
Dermatol Ther. 2020 Sep 22. doi: 10.1111/dth.14323. Online ahead of print. Case report.
https://doi.org/10.1111/dth.14323

COVID and biologics.
Elston DM.
J Am Acad Dermatol. 2020 Sep 11:S0190-9622(20)32595-0. doi: 10.1016/j.jaad.2020.09.010. Online ahead of print. Commentary.
https://doi.org/10.1016/j.jaad.2020.09.010

COVID-19 and systemic therapies in psoriasis: experience of a tertiary hospital in Madrid.
Fulgencio-Barbarin J, Puerta-Peña M, Ortiz-Romero P, García-Donoso C, Rivera-Diaz R.
Int J Dermatol. 2020 Sep 4. doi: 10.1111/ijd.15157. Online ahead of print. Report / audit.
https://doi.org/10.1111/ijd.15157

Nonadherence to treatment and patient-reported outcomes of psoriasis during the COVID-19 epidemic: A web-based survey.
Wang Q, Luo Y, Lv C, Zheng X, Zhu W, Chen X, Shen M, Kuang Y.
Patient Prefer Adherence. 2020 Aug 7;14:1403-1409. doi: 10.2147/PPA.S263843. eCollection 2020. Survey / cross-sectional study.
https://doi.org/10.2147/ppa.s263843

COVID‐19 und Auswirkungen auf dermatologische und allergologische Erkrankungen.
Buhl T, Beissert S, Gaffal E, Goebeler M, Hertl M, Mauch C, Reich K, Schmidt E, Schön MP, Sticherling M, Sunderkötter C, Traidl-Hoffmann C, Werfel T, Wilsman-Theis D, Worm M.
J Dtsch Dermatol Ges. 2020 Aug;18(8):815-825. doi: 10.1111/ddg.14195_g. Review. German.
https://doi.org/10.1111/ddg.14195_g

Effect of anti-tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in psoriasis patients - A meta-estimate of pivotal phase 3 trials relevant to decision-making during the COVID-19 pandemic.
Syed MN, Shah M, Shin DB, Wan MT, Winthrop KL, Gelfand JM.
J Am Acad Dermatol. 2020 Aug 26:S0190-9622(20)32492-0. doi: 10.1016/j.jaad.2020.08.095. Online ahead of print. Trial meta-analysis.
https://doi.org/10.1016/j.jaad.2020.08.095

Use of immunosuppressants/immunomodulators in autoimmune/inflammatory dermatologic diseases during COVID-19 pandemic - General recommendation based on available evidence.
De D, Pandhi D.
Indian Dermatol Online J. 2020 Jul 13;11(4):526-533. doi: 10.4103/idoj.IDOJ_414_20. eCollection 2020 Jul-Aug. Review / recommendations.
https://doi.org/10.4103/idoj.idoj_414_20

Effect of immunosuppressive drugs in immune-mediated inflammatory disease during the coronavirus pandemic.
Giuliani F, Gualdi G, Amerio P.
Dermatol Ther. 2020 Aug 23. doi: 10.1111/dth.14204. Online ahead of print. Systematic review.
https://doi.org/10.1111/dth.14204

Lack of evidence for an increased risk of severe COVID-19 in psoriasis patients on biologics: A cohort study from northeast Italy.
Piaserico S, Gisondi P, Cazzaniga S, Naldi L.
Am J Clin Dermatol. 2020 Aug 18. doi: 10.1007/s40257-020-00552-w. Online ahead of print. Cohort study.
https://doi.org/10.1007/s40257-020-00552-w

Coronavirus disease 2019 in a psoriatic patient with concomitant chronic obstructive pulmonary disease under treatment with risankizumab.
Kiss N, Lőrincz K, Medvecz M, Fésűs L, Csuha P, Hermányi Z, Wikonkál NM.
Dermatol Ther. 2020 Aug 14:e14186. doi: 10.1111/dth.14186. Online ahead of print. Case report.
https://doi.org/10.1111/dth.14186

Severe COVID-19 outcomes in patients with psoriasis.
Lima XT, Cueva MA, Lopes EM, Alora MB.
J Eur Acad Dermatol Venereol. 2020 Aug 11. doi: 10.1111/jdv.16867. Online ahead of print. Retrospective cohort study.
https://doi.org/10.1111/jdv.16867

Concerns related to the COVID-19 pandemic in adult patients with atopic dermatitis and psoriasis treated with systemic immunomodulatory therapy: a Danish questionnaire survey.
Dyrberg Loft N, Halling AS, Iversen L, Vestergaard C, Deleuran M, Rasmussen MK, Zachariae C, Thyssen JP, Skov L.
J Eur Acad Dermatol Venereol. 2020 Aug 11. doi: 10.1111/jdv.16863. Online ahead of print. Survey.
https://doi.org/10.1111/jdv.16863

Dupilumab in atopic dermatitis, a protocol for SARS-COV 2 infected patients.
Ordóñez-Rubiano MF, Campo I, Casas M.
Dermatol Ther. 2020 Aug 10:e14172. doi: 10.1111/dth.14172. Online ahead of print. Case report / commentary.
https://doi.org/10.1111/dth.14172

Guttate psoriasis secondary to COVID-19.
Gananandan K, Sacks B, Ewing I.
BMJ Case Rep. 2020 Aug 11;13(8):e237367. doi: 10.1136/bcr-2020-237367. Case report.
https://doi.org/10.1136/bcr-2020-237367

Examining recommendations for the use of biologics and other systemic therapies during COVID-19: a review and comparison of available dermatology guidelines and patient registries.
Gadarowski MB, Balogh EA, Bashyam AM, Feldman SR.
J Dermatolog Treat. 2020 Aug 8:1-17. doi: 10.1080/09546634.2020.1808154. Online ahead of print. Review.
https://doi.org/10.1080/09546634.2020.1808154

Biologic drugs during COVID-19 outbreak.
Montesu MA, Biondi G, Sotgiu G, Sucato F, Satta R.
Int J Dermatol. 2020 Aug 6. doi: 10.1111/ijd.15088. Online ahead of print. Cohort study.
https://doi.org/10.1111/ijd.15088

COVID-19 and immunosuppressive therapy in dermatology.
Schwartz RA, Pradhan S, Murrell DF, Jafferany M, Olisova OY, Lomonosov KM, Lotti T, Goldust M.
Dermatol Ther. 2020 Aug 7:e14140. doi: 10.1111/dth.14140. Online ahead of print. Review / recommendations.
https://doi.org/10.1111/dth.14140

Severe acute respiratory syndrome coronavirus 2 and the use of biologics in patients with psoriasis.
Ladda M, Lynde C, Fleming P.
J Cutan Med Surg. 2020 Aug 6:1203475420945234. doi: 10.1177/1203475420945234. Online ahead of print. Review.
https://doi.org/10.1177/1203475420945234

Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy.
Talamonti M, Galluzzo M, Chiricozzi A, Quaglino P, Fabbrocini G, Gisondi P, Marzano AV, Potenza C, Conti A, Parodi A, Belloni Fortina A, Bardazzi F, Argenziano G, Rongioletti F, Stingeni L, Micali G, Loconsole F, Venturini M, Bongiorno MR, Feliciani C, Rubegni P, Amerio P, Fargnoli MC, Pigatto P, Savoia P, Nisticò SP, Giustini S, Carugno A, Cannavò SP, Rech G, Prignano F, Offidani A, Lombardo M, Zalaudek I, Bianchi L, Peris K; PSO-BIO-COVID study group.
J Eur Acad Dermatol Venereol. 2020 Jul 31. doi: 10.1111/jdv.16841. Online ahead of print. Multicentre observational study.
https://doi.org/10.1111/jdv.16841

COVID-19 and implications for dermatological and allergological diseases.
Buhl T, Beissert S, Gaffal E, Goebeler M, Hertl M, Mauch C, Reich K, Schmidt E, Schön MP, Sticherling M, Sunderkötter C, Traidl-Hoffmann C, Werfel T, Wilsman-Theis D, Worm M.
J Dtsch Dermatol Ges. 2020 Jul 27. doi: 10.1111/ddg.14195. Online ahead of print. Review.
https://doi.org/10.1111/ddg.14195

How infodemic during the COVID-19 outbreak influenced common clinical practice in an Outpatient Service of severe psoriasis.
Sacchelli L, Evangelista V, Di Altobrando A, Lacava R, Rucci P, Rosa S, Patrizi A, Bardazzi F.
Dermatol Ther. 2020 Jul 26:e14065. doi: 10.1111/dth.14065. Online ahead of print. Prospective cohort study.
https://doi.org/10.1111/dth.14065

The impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biological therapies.
Pirro F, Caldarola G, Chiricozzi A, Tambone S, Mariani M, Calabrese L, D'Urso DF, De Simone C, Peris K.
J Dermatolog Treat. 2020 Jul 24:1-14. doi: 10.1080/09546634.2020.1800578. Online ahead of print. Survey / cross-sectional study.
https://doi.org/10.1080/09546634.2020.1800578

A case of severe psoriatic erythroderma with COVID-19.
Ghalamkarpour F, Pourani MR, Abdollahimajd F, Zargari O.
J Dermatolog Treat. 2020 Jul 21:1-11. doi: 10.1080/09546634.2020.1799918. Online ahead of print. Case report.
https://doi.org/10.1080/09546634.2020.1799918

Psoriasis and COVID-19: A narrative review with treatment considerations.
Elmas ÖF, Demirbaş A, Kutlu Ö, Bağcıer F, Metin MS, Özyurt K, Akdeniz N, Atasoy M, Türsen Ü, Lotti T.
Dermatol Ther. 2020 Jun 17:e13858. doi: 10.1111/dth.13858. Online ahead of print.
https://doi.org/10.1111/dth.13858

Treatment discontinuation and rate of disease transmission in psoriasis patients on biologic therapy during the COVID-19 pandemic - A Canadian multicenter retrospective study.
Georgakopoulos JR, Mufti A, Vender R, Yeung J.
J Am Acad Dermatol. 2020 Jul 14. pii: S0190-9622(20)32185-X. doi: 10.1016/j.jaad.2020.07.021. [Epub ahead of print] No abstract available. Retrospective study / case review.
https://doi.org/10.1016/j.jaad.2020.07.021

Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces.
Vispi M, Corradin T, Peccianti C, Feci L, Casini L, Pisani C, Fabbroni S, Corsetti P, Croatto M, Pellegrino M.
Dermatol Reports. 2020 Jun 25;12(1):8642. doi: 10.4081/dr.2020.8642. eCollection 2020 Jun 25. Report / audit.
https://doi.org/10.4081/dr.2020.8642

Coronavirus disease 2019 (COVID-19) rash in a psoriatic patient treated with Secukinumab: is there a role for Interleukin 17?
Carugno A, Gambini DM, Raponi F, Vezzoli P, Robustelli Test E, Arosio MEG, Callegaro A, Sena P.
Dermatol Ther. 2020 Jul 12:e14011. doi: 10.1111/dth.14011. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/dth.14011

Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions?
Talamonti M, Tofani L, Bianchi L, Galluzzo M.
Arch Dermatol Res. 2020 Jul 9. doi: 10.1007/s00403-020-02103-z. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1007/s00403-020-02103-z

Patient´s perspective: psychological burden of the COVID-19 pandemic in 146 psoriatic patients treated with biological drugs and small molecules in real clinical practice.
Rodríguez-Villa Lario A, Vega-Díez D, González-Cañete M, Polo-Rodríguez I, Piteiro-Bermejo AB, Herrero-Fernández M, Arévalo-Serrano J, Trasobares-Marugán L, Medina-Montalvo S.
J Dermatolog Treat. 2020 Jul 9:1-9. doi: 10.1080/09546634.2020.1790485. [Epub ahead of print] No abstract available. Retrospective chart review.
https://doi.org/10.1080/09546634.2020.1790485

Risk of COVID-19 in dermatologic patients on long-term immunomodulatory therapy.
Holcomb ZE, Santillan MR, Morss-Walton PC, Salian P, Her MJ, Giannotti NM, Kimball AB, Porter ML.
J Am Acad Dermatol. 2020 Jul 1. pii: S0190-9622(20)32099-5. doi: 10.1016/j.jaad.2020.06.999. [Epub ahead of print] No abstract available. Retrospective cross-sectional study.
https://doi.org/10.1016/j.jaad.2020.06.999

The risk of respiratory tract infections in psoriasis patients treated with IL-23-pathway inhibiting biologics: A meta-estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic.
Syed MN, Shin DB, Wan MT, Winthrop KL, Gelfand JM.
J Am Acad Dermatol. 2020 Jul 2. pii: S0190-9622(20)32115-0. doi: 10.1016/j.jaad.2020.06.1014. [Epub ahead of print] No abstract available. Meta-analysis.
https://doi.org/10.1016/j.jaad.2020.06.1014

COVID-19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy versus apremilast in North Spain.
Queiro Silva R, Armesto S, González Vela C, Naharro Fernández C, González-Gay MA.
Dermatol Ther. 2020 Jul 3:e13961. doi: 10.1111/dth.13961. [Epub ahead of print]. Case series.
https://doi.org/10.1111/dth.13961

Compliance, safety concerns and anxiety in patients treated with biologics for psoriasis during the COVID-19 pandemic national lockdown: A multicenter study in the Czech Republic.
Rob F, Hugo J, Tivadar S, Boháč P, Gkalpakiotis S, Vargová N, Arenbergerová M, Hercogová J.
J Eur Acad Dermatol Venereol. 2020 Jun 27. doi: 10.1111/jdv.16771. [Epub ahead of print]. Prospective research study.
https://doi.org/10.1111/jdv.16771

COVID-19 and psoriasis: Biologic treatment and challenges.
Ebrahimi A, Sayad B, Rahimi Z.
J Dermatolog Treat. 2020 Jun 29:1-14. doi: 10.1080/09546634.2020.1789051. [Epub ahead of print]. Review.
https://doi.org/10.1080/09546634.2020.1789051

Treatment of psoriasis - unburdened by fear during SARS-CoV2 menace.
Timis TL, Florian IA, Vesa SC, Orasan RI.
J Dermatolog Treat. 2020 Jun 27:1-10. doi: 10.1080/09546634.2020.1788704. [Epub ahead of print]. Review / commentary.
https://doi.org/10.1080/09546634.2020.1788704

COVID-19 infection on IL-23 inhibition.
Wang CJ, Truong AK.
Dermatol Ther. 2020 Jun 25. doi: 10.1111/dth.13893. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/dth.13893

Psoriasis and COVID-19: a multifactorial consideration.
Cohen JM, Perez-Chada LM, De Kouchkovsky D, Gehlhausen JR.
J Dermatolog Treat. 2020 Jun 22:1. doi: 10.1080/09546634.2020.1782818. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1080/09546634.2020.1782818

Clinical management of psoriasis patients during the COVID-19 pandemic.
Chat VS, Uppal SK, Kearns DG, Wu JJ.
J Dermatolog Treat. 2020 Jun 22:1-2. doi: 10.1080/09546634.2020.1781045. [Epub ahead of print]. Review / commentary.
https://doi.org/10.1080/09546634.2020.1781045

Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19.
Fougerousse AC, Perrussel M, Bécherel PA, Begon E, Pallure V, Zaraa I, Chaby G, Parier J, Kemula M, Mery-Bossard L, Poreaux C, Taieb C, Maccari F, Reguiai Z; GEM Resopso.
J Eur Acad Dermatol Venereol. 2020 Jun 21. doi: 10.1111/jdv.16761. [Epub ahead of print]. Multicentre, cross-sectional study.
https://doi.org/10.1111/jdv.16761

'Treatment adherence in psoriatic patients during COVID-19 pandemic: Real-world data from a tertiary hospital in Greece''.
Vakirlis AE, Bakirtzi K, Papadimitriou I, Vrani F, Sideris N, Lallas A, Ioannides D, Sotiriou E.
J Eur Acad Dermatol Venereol. 2020 Jun 18. doi: 10.1111/jdv.16759. [Epub ahead of print]. Survey / observational study.
https://doi.org/10.1111/jdv.16759

Complicated coronavirus disease 2019 (COVID-19) in a psoriatic patient treated with ixekizumab.
Facheris P, Valenti M, Pavia G, Gargiulo L, Narcisi A, Costanzo A, Borroni RG.
Int J Dermatol. 2020 Jun 18. doi: 10.1111/ijd.15008. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/ijd.15008

Patients with specific skin disorders who are affected by COVID-19: what do experiences say about management strategies? : A systematic review.
Najar Nobar N, Goodarzi A.
Dermatol Ther. 2020 Jun 18:e13867. doi: 10.1111/dth.13867. [Epub ahead of print]. Systematic review.
https://doi.org/10.1111/dth.13867

Risk of infections in psoriasis. A lesson to learn during the SARS-CoV-2 pandemic.
Naldi L.
Br J Dermatol. 2020 Jun 15. doi: 10.1111/bjd.19190. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1111/bjd.19190

Psoriasis and risk of the COVID-19 infection: Is there a role for Angiotensin Converting Enzyme (ACE)?
Shahidi-Dadras M, Tabary M, Robati RM, Araghi F, Dadkhahfar S.
J Dermatolog Treat. 2020 Jun 16:1-7. doi: 10.1080/09546634.2020.1782819. [Epub ahead of print]. Commentary.
https://doi.org/10.1080/09546634.2020.1782819

Comment on "Psoriasis, COVID-19 and acute respiratory distress syndrome: focusing on the risk of concomitant biological treatment".
Farabi B, Bhargava S, Goldust M, Atak MF.
Dermatol Ther. 2020 Jun 14:e13840. doi: 10.1111/dth.13840. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1111/dth.13840

COVID-19 era: A chance to learn something new about monitoring psoriatic patients in biological therapy.
Filippi F, Loi C, Evangelista V, Bardazzi F.
Dermatol Ther. 2020 Jun 10:e13805. doi: 10.1111/dth.13805. [Epub ahead of print] No abstract available. Report / audit.
https://doi.org/10.1111/dth.13805

Biologic agents in psoriasis: our experience during coronavirus infection.
Strippoli D, Barbagallo T, Prestinari F, Russo G, Fantini F.
Int J Dermatol. 2020 Jun 9. doi: 10.1111/ijd.15002. [Epub ahead of print] No abstract available. Cross-sectional study.
https://doi.org/10.1111/ijd.15002

Intramatricial methotrexate for treatment of resistant acrodermatitis continua of Hallopeau: an alterative in Covid-19.
Jindal A, Ramesh S, Noronha M, Pai K, Pai S.
Dermatol Ther. 2020 Jun 8:e13787. doi: 10.1111/dth.13787. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/dth.13787 

Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era.
Galluzzo M, Tofani L, Bianchi L, Talamonti M.
Expert Opin Biol Ther. 2020 Jun 8. doi: 10.1080/14712598.2020.1779217. [Epub ahead of print] No abstract available. Commentary/ cohort study.
https://doi.org/10.1080/14712598.2020.1779217

Psoriasis-COVID 19 infection: Treatment options.
Tampouratzi E, Kanni T, Katsantonis J, Douvali T.
Skinmed. 2020 Mar 1;18(2):81-82. eCollection 2020. No abstract available. Commentary?
https://pubmed.ncbi.nlm.nih.gov/32501789/

Recommendations for treatment of nail psoriasis during the COVID-19 pandemic.
Ricardo JW, Lipner SR.
Dermatol Ther. 2020 Jun 4:e13757. doi: 10.1111/dth.13757. [Epub ahead of print] No abstract available. Review / recommendations.
https://doi.org/10.1111/dth.13757

Rate of patient-driven biologic treatment discontinuation during the COVID-19 pandemic in 2 academic hospital clinics at the University of Toronto.
Georgakopoulos JR, Yeung J.
J Cutan Med Surg. 2020 Jun 1:1203475420930226. doi: 10.1177/1203475420930226. [Epub ahead of print] No abstract available. Multicentre retrospective case review.
https://doi.org/10.1177/1203475420930226

Psoriasis, biologic therapy, and the pandemic of the 21st century.
Nogueira M, Vender R, Torres T.
Drugs Context. 2020 May 14;9. pii: 2020-4-10. doi: 10.7573/dic.2020-4-10. eCollection 2020. Editorial.
https://doi.org/10.7573/dic.2020-4-10

Covid-19 infection in psoriasis patients treated with cyclosporin.
Di Lernia V, Goldust M, Feliciani C.
Dermatol Ther. 2020 Jun 1. doi: 10.1111/dth.13739. [Epub ahead of print] No abstract available. Case series.
https://doi.org/10.1111/dth.13739

Psoriasis, COVID-19 and acute respiratory distress syndrome: focusing on the risk of concomitant biological treatment.
Magnano M, Balestri R, Bardazzi F, Mazzatenta C, Girardelli CR, Rech G.
Dermatol Ther. 2020 May 30. doi: 10.1111/dth.13706. [Epub ahead of print] No abstract available. Case series.
https://doi.org/10.1111/dth.13706

Clinical efficacy, speed of improvement and safety of apremilast for the treatment of adult psoriasis during COVID-19 pandemic.
Melis D, Mugheddu C, Sanna S, Atzori L, Rongioletti F.
Dermatol Ther. 2020 May 30:e13722. doi: 10.1111/dth.13722. [Epub ahead of print]. Case series.
https://doi.org/10.1111/dth.13722

Non-complicated evolution of COVID-19 infection in a patient with psoriasis and psoriatic arthritis during treatment with adalimumab.
Valenti M, Facheris P, Pavia G, Gargiulo L, Borroni RG, Costanzo A, Narcisi A.
Dermatol Ther. 2020 May 30. doi: 10.1111/dth.13708. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/dth.13708

Novel coronavirus disease (COVID-19) and biologic therapy for psoriasis: Successful recovery in two patients after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Brownstone ND, Thibodeaux QG, Reddy VD, Myers BA, Chan SY, Bhutani T, Liao W.
Dermatol Ther (Heidelb). 2020 May 29. doi: 10.1007/s13555-020-00394-8. [Epub ahead of print]. Case reports.
https://doi.org/10.1007/s13555-020-00394-8

Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic.
Ricardo JW, Lipner SR.
Dermatol Ther. 2020 May 27. doi: 10.1111/dth.13687. [Epub ahead of print]. Review.
https://doi.org/10.1111/dth.13687

Use of systemic therapies for psoriasis in the COVID-19 era.
Kearns DG, Uppal S, Chat VS, Wu JJ.
J Dermatolog Treat. 2020 May 27:1-14. doi: 10.1080/09546634.2020.1775774. [Epub ahead of print]. Review of guidelines.
https://doi.org/10.1080/09546634.2020.1775774

Apremilast as a potential treatment option for COVID-19: no symptoms of infection in a psoriatic patient.
Yu Olisova O, Anpilogova EM, Svistunova DA.
Dermatol Ther. 2020 May 24:e13668. doi: 10.1111/dth.13668. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/dth.13668

Hydroxychloroquine effects on psoriasis: a systematic review and a cautionary note for COVID-19 treatment.
Sachdeva M, Mufti A, Maliyar K, Lytvyn Y, Yeung J.
J Am Acad Dermatol. 2020 May 19. pii: S0190-9622(20)30942-7. doi: 10.1016/j.jaad.2020.05.074. [Epub ahead of print]. Systematic review.
https://doi.org/10.1016/j.jaad.2020.05.074

Covid-19 and exacerbation of psoriasis.
Ozaras R, Berk A, Ucar DH, Duman H, Kaya F, Mutlu H.
Dermatol Ther. 2020 May 20. doi: 10.1111/dth.13632. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/dth.13632

Patient-driven discontinuation of dupilumab during the COVID-19 pandemic in two academic hospital clinics at the University of Toronto.
Georgakopoulos JR, Yeung J.
J Cutan Med Surg. 2020 May 20:1203475420930223. doi: 10.1177/1203475420930223. [Epub ahead of print] No abstract available. Retrospective cross-sectional study.
https://doi.org/10.1177/1203475420930223

Opportunistic virus infections in psoriasis patients: the safer alternative of apremilast.
Armesto S, González Vela C, González López MA.
Dermatol Ther. 2020 May 18:e13618. doi: 10.1111/dth.13618. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1111/dth.13618

Evidenced-based best practice advice for patients treated with systemic immunosuppressants in relation to COVID-19.
Galimberti F, McBride J, Cronin M, Li Y, Fox J, Abrouk M, Herbst A, Kirsner RS.
Clin Dermatol. 2020 May 14. doi: 10.1016/j.clindermatol.2020.05.003. [Epub ahead of print]. Review / recommendations.
https://doi.org/10.1016/j.clindermatol.2020.05.003

The risk of respiratory tract infections and symptoms in psoriasis patients treated with IL-17-pathway inhibiting biologics: A meta-estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic.
Wan MT, Shin DB, Winthrop KL, Gelfand JM.
J Am Acad Dermatol. 2020 May 13. pii: S0190-9622(20)30866-5. doi: 10.1016/j.jaad.2020.05.035. [Epub ahead of print] No abstract available. Meta-analysis.
https://doi.org/10.1016/j.jaad.2020.05.035

Association of outdoor activity restriction and income loss with patient-reported outcomes of psoriasis during the COVID-19 pandemic: A web-based survey.
Kuang Y, Shen M, Wang Q, Xiao Y, Lv C, Luo Y, Zhu W, Chen X.
J Am Acad Dermatol. 2020 May 11. pii: S0190-9622(20)30846-X. doi: 10.1016/j.jaad.2020.05.018. [Epub ahead of print] No abstract available. Survey / cross-sectional study.
https://doi.org/10.1016/j.jaad.2020.05.018

A survey of psoriasis patients on biologics during COVID-19: a single centre experience.
Burlando M, Carmisciano L, Cozzani E, Parodi A.
J Dermatolog Treat. 2020 May 14:1-3. doi: 10.1080/09546634.2020.1770165. [Epub ahead of print] No abstract available. Survey.
https://doi.org/10.1080/09546634.2020.1770165

COVID-19 in an elderly patient treated with secukinumab.
Di Lernia V, Bombonato C, Motolese A.
Dermatol Ther. 2020 May 13:e13580. doi: 10.1111/dth.13580. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/dth.13580

Is the coronavirus (COVID-19) pandemic an indication to temporarily modify dermatological management plans?
Shanshal M.
J Drugs Dermatol. 2020 Apr 1;19(4):436. No abstract available. Commentary.
http://jddonline.com/articles/dermatology/S1545961620P0436X

Patient-driven discontinuation of apremilast during the COVID-19 pandemic in two Canadian academic hospital clinics and one community practice.
Georgakopoulos JR, Vender R, Yeung J. Multicenter retrospective study.
J Cutan Med Surg. 2020 May 12:1203475420928382. doi: 10.1177/1203475420928382. [Epub ahead of print]
https://doi.org/10.1177/1203475420928382

COVID-19 and biologics for psoriasis: a high-epidemic area experience - Bergamo, Lombardy, Italy.
Carugno A, Gambini DM, Raponi F, Vezzoli P, Locatelli AGC, Di Mercurio M, Test ER, Sena P.
J Am Acad Dermatol. 2020 May 6. pii: S0190-9622(20)30819-7. doi: 10.1016/j.jaad.2020.04.165. [Epub ahead of print] No abstract available. Case reports & commentary.
https://doi.org/10.1016/j.jaad.2020.04.165

COVID-19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management.
Mugheddu C, Pizzatti L, Sanna S, Atzori L, Rongioletti F.
J Eur Acad Dermatol Venereol. 2020 May 9. doi: 10.1111/jdv.16625. [Epub ahead of print]. Case report.
https://doi.org/10.1111/jdv.16625

Evolution of COVID-19 infection in 4 psoriatic patients treated with biological drugs.
Conti A, Lasagni C, Bigi L, Pellacani G.
J Eur Acad Dermatol Venereol. 2020 May 7. doi: 10.1111/jdv.16587. [Epub ahead of print]. Case series.
https://doi.org/10.1111/jdv.16587

Improvement of SARS-CoV2 symptoms following guselkumab injection in a psoriatic patient.
Benhadou F, Del Marmol V.
J Eur Acad Dermatol Venereol. 2020 May 7. doi: 10.1111/jdv.16590. [Epub ahead of print]. Case report.
https://doi.org/10.1111/jdv.16590

Covid-19 in immune-mediated inflammatory diseases - Case series from New York.
Haberman R, Axelrad J, Chen A, Castillo R, Yan D, Izmirly P, Neimann A, Adhikari S, Hudesman D, Scher JU.
N Engl J Med. 2020 Apr 29. doi: 10.1056/NEJMc2009567. [Epub ahead of print] No abstract available. Case series.
https://doi.org/10.1056/NEJMc2009567

Dermatological diseases presented before COVID-19: Are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19?
Kutlu Ö, Metin A.
Dermatol Ther. 2020 May 5:e13509. doi: 10.1111/dth.13509. [Epub ahead of print]. Case series.
https://doi.org/10.1111/dth.13509

A challenging case of psoriasis flare-up after COVID-19 infection.
Nasiri S, Araghi F, Tabary M, Gheisari M, Mahboubi-Fooladi Z, Dadkhahfar S.
J Dermatolog Treat. 2020 May 2:1-6. doi: 10.1080/09546634.2020.1764904. [Epub ahead of print]. Case report.
https://doi.org/10.1080/09546634.2020.1764904

Biologic therapy for psoriasis during the COVID-19 outbreak: the choice is to weigh risks and benefits.
Conforti C, Giuffrida R, Dianzani C, Di Meo N, Zalaudek I.
Dermatol Ther. 2020 May 1:e13490. doi: 10.1111/dth.13490. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1111/dth.13490

Comment on "Antipsoriatic treatments during COVID-19 outbreak".
Abdelmaksoud A, Goldust M, Vestita M.
Dermatol Ther. 2020 May 1:e13491. doi: 10.1111/dth.13491. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1111/dth.13491

Dermatology patients' knowledge and concerns regarding their immunomodulatory medication during the COVID-19 pandemic.
Keeling E, Daly S, McKenna DB.
Dermatol Ther. 2020 May 1:e13488. doi: 10.1111/dth.13488. [Epub ahead of print] No abstract available. Survey.
https://doi.org/10.1111/dth.13488

Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic.
Mahil SK, Yiu ZZN, Mason KJ, Dand N, Coker B, Wall D, Fletcher G, Bosma A, Capon F, Iversen L, Langan SM, Di Meglio P, Musters A, Prieto-Merino D, Tsakok T, Warren RB, Flohr C, Spuls P, Griffiths CEM, Barker J, Irvine AD, Smith CH; Secure-AD, PsoPROTECT study groups.
Br J Dermatol. 2020 Apr 29. doi: 10.1111/bjd.19161. [Epub ahead of print]. Letter/commentary.
https://doi.org/10.1111/bjd.19161

The impact of COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biologic therapy: the Northern Italy experience.
Gisondi P, Facheris P, Dapavo P, Piaserico S, Conti A, Naldi L, Cazzaniga S, Malagoli P, Costanzo A.
Br J Dermatol. 2020 Apr 28. doi: 10.1111/bjd.19158. [Epub ahead of print]. Multicentre observational study.
https://doi.org/10.1111/bjd.19158

Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biological treatment and renal transplanted recipients in maintenance immunosuppressive treatment.
Gisondi P, Zaza G, Del Giglio M, Rossi M, Iacono V, Girolomoni G.
J Am Acad Dermatol. 2020 Apr 21. pii: S0190-9622(20)30701-5. doi: 10.1016/j.jaad.2020.04.085. [Epub ahead of print] No abstract available.
https://doi.org/10.1016/j.jaad.2020.04.085

Immunomodulators and immunosuppressants in the era of SARS-CoV-2 - could laboratory tests be the missing link?
Alpalhão M, Filipe P.
J Dermatolog Treat. 2020 Apr 23:1-8. doi: 10.1080/09546634.2020.1760195. [Epub ahead of print] No abstract available.
https://doi.org/10.1080/09546634.2020.1760195

COVID-19 and psoriasis : should we fear for patients treated with biologics?
Amerio P, Prignano F, Giuliani F, Gualdi G.
Dermatol Ther. 2020 Apr 20. doi: 10.1111/dth.13434. [Epub ahead of print]
https://doi.org/10.1111/dth.13434

Novel coronavirus disease (COVID-19) and biologic therapy in psoriasis: Infection risk and patient counseling in uncertain times.
Brownstone ND, Thibodeaux QG, Reddy VD, Myers BA, Chan SY, Bhutani T, Liao W.
Dermatol Ther (Heidelb). 2020 Apr 16:1-11. doi: 10.1007/s13555-020-00377-9. [Epub ahead of print]
https://doi.org/10.1007/s13555-020-00377-9

Novel coronavirus disease (COVID-19) and biologic therapy in psoriasis: Infection risk and patient counseling in uncertain times.
Brownstone ND, Thibodeaux QG, Reddy VD, Myers BA, Chan SY, Bhutani T, Liao W.
Dermatol Ther (Heidelb). 2020 Apr 16. doi: 10.1007/s13555-020-00377-9. [Epub ahead of print]
https://doi.org/10.1007/s13555-020-00377-9

Psoriasis and psoriatic arthritis: how to manage immunosuppressants in COVID-19 days.
Coletto LA, Favalli EG, Caporali R.
Dermatol Ther. 2020 Apr 14:e13415. doi: 10.1111/dth.13415. [Epub ahead of print] No abstract available.
https://doi.org/10.1111/dth.13415

SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor.
Messina F, Piaserico S.
J Eur Acad Dermatol Venereol. 2020 Apr 15. doi: 10.1111/jdv.16468. [Epub ahead of print]
https://doi.org/10.1111/jdv.16468

Psoriasis health care in the time of the coronavirus pandemic: insights from dedicated centers in sardinia (Italy).
Atzori L, Mugheddu C, Addis G, Sanna S, Satta R, Ferreli C, Atzori MG, Montesu MA, Rongioletti F.
J Eur Acad Dermatol Venereol. 2020 Apr 15. doi: 10.1111/jdv.16473. [Epub ahead of print]
https://doi.org/10.1111/jdv.16473

Managing cutaneous immune-mediated diseases during the COVID-19 pandemic.
Torres T, Puig L.
Am J Clin Dermatol. 2020 Apr 10. doi: 10.1007/s40257-020-00514-2. [Epub ahead of print]
https://doi.org/10.1007/s40257-020-00514-2

SECURE-Psoriasis: A de-identified registry of psoriasis patients diagnosed with COVID-19.
Balogh EA, Heron C, Feldman SR, Huang WW.
J Dermatolog Treat. 2020 Apr 8:1-2. doi: 10.1080/09546634.2020.1753996. [Epub ahead of print] No abstract available.
https://doi.org/10.1080/09546634.2020.1753996

A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: Will cases of psoriasis increase after COVID-19 pandemic?
Kutlu Ö, Metin A.
Dermatol Ther. 2020 Apr 7:e13383. doi: 10.1111/dth.13383. [Epub ahead of print] No abstract available.
https://doi.org/10.1111/dth.13383

The COVID-19 outbreak and rheumatologic skin diseases.
Arora G, Kassir M, Jafferany M, Galadari H, Lotti T, Satolli F, Sadoughifar R, Sitkowska Z, Goldust M.
Dermatol Ther. 2020 Mar 31:e13357. doi: 10.1111/dth.13357. [Epub ahead of print] No abstract available.
https://doi.org/10.1111/dth.13357

Antipsoriatic treatments during COVID-19 outbreak.
Di Lernia V.
Dermatol Ther. 2020 Mar 29:e13345. doi: 10.1111/dth.13345. [Epub ahead of print] No abstract available.
https://doi.org/10.1111/dth.13345 

 

Back to CEBD Coronavirus Dermatology Resource Homepage

Centre of Evidence Based Dermatology

The University of Nottingham
King's Meadow Campus
Lenton Lane
Nottingham, NG7 2NR


telephone: +44 (0) 115 823 1048
email:cebd@nottingham.ac.uk